172 related articles for article (PubMed ID: 29721481)
1. Practical consensus recommendations regarding the use of hormonal therapy in metastatic breast cancer.
Rajappa S; Bajpai J; Basade M; Ganvir M; Goswami C; Murali A; Rathi AK; Kaushal V; Jain S; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):137-141. PubMed ID: 29721481
[TBL] [Abstract][Full Text] [Related]
2. Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer.
Basade M; Singhal M; Rathi AK; Nandi M; Minhas S; Goswami C; Shinde S; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):146-150. PubMed ID: 29721483
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
4. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
5. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Rugo HS; Rumble RB; Macrae E; Barton DL; Connolly HK; Dickler MN; Fallowfield L; Fowble B; Ingle JN; Jahanzeb M; Johnston SR; Korde LA; Khatcheressian JL; Mehta RS; Muss HB; Burstein HJ
J Clin Oncol; 2016 Sep; 34(25):3069-103. PubMed ID: 27217461
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
8. Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer.
Gupta S; Singh M; Vora A; Babu G; Walia M; Nautial V; Saha R; Smruti BK; Sharma JB; Koul R; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):142-145. PubMed ID: 29721482
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
10. Practical consensus recommendations on management of triple-negative metastatic breast cancer.
Rangarao R; Smruti BK; Singh K; Gupta A; Batra S; Choudhary RK; Gupta A; Sahani S; Kabra V; Parikh PM; Aggarwal S
South Asian J Cancer; 2018; 7(2):127-131. PubMed ID: 29721479
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
12. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
13. ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.
Parikh PM; Gupta S; Dawood S; Rugo H; Bhattacharyya GS; Agarwal A; Chacko R; Sahoo TP; Babu G; Agarwal S; Munshi A; Goswami C; Smruti BK; Bondarde S; Desai C; Rajappa S; Somani N; Singh M; Nimmagadda R; Pavitran K; Mehta A; Parmar V; Desai S; Nair R; Doval D
Indian J Cancer; 2014; 51(1):73-9. PubMed ID: 24947101
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
[TBL] [Abstract][Full Text] [Related]
15. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.
Perez EA
Drug Resist Updat; 2016 Jan; 24():13-22. PubMed ID: 26830312
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
19. Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective.
Marchetti P; Maass N; Gligorov J; Berger K; MacDougall F; Montonen J; Lewis J
Breast; 2017 Apr; 32():247-255. PubMed ID: 28011074
[TBL] [Abstract][Full Text] [Related]
20. Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women.
Babu G; Goel A; Agarwal S; Gupta S; Kumar P; Smruti BK; Goel V; Sarangi R; Gairola M; Aggarwal S; Parikh PM
South Asian J Cancer; 2018; 7(2):123-126. PubMed ID: 29721478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
